VX-765: Selective Caspase-1 Inhibitor for Pyroptosis Research

Executive Summary: VX-765 is an orally bioavailable pro-drug inhibitor of caspase-1, validated for selective modulation of IL-1β and IL-18 in inflammation and pyroptosis models (source: product_spec). Its active metabolite, VRT-043198, is responsible for caspase-1 inhibition in vivo (source: product_spec). VX-765 suppresses pyroptotic cell death in macrophages and endothelial cells without affecting unrelated cytokines (source: Yuan et al. 2022). The compound is highly soluble in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL, ultrasonic), but insoluble in water (source: product_spec). APExBIO provides VX-765 as reference-grade material for biochemical and translational research (source: product_spec).

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease central to innate immune responses. It processes pro-IL-1β and pro-IL-18 into their active, secreted forms, driving inflammatory signaling and pyroptosis—a form of programmed necrotic cell death associated with inflammasome activation (source: Yuan et al. 2022). Dysregulated caspase-1 activity contributes to disease pathogenesis in atherosclerosis, rheumatoid arthritis, and HIV-related immune depletion. Pyroptosis, unlike apoptosis, leads to rapid cell membrane rupture and the release of pro-inflammatory cytokines, amplifying tissue damage (source: Yuan et al. 2022).

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is an orally absorbed pro-drug that is converted in vivo to its active form, VRT-043198 (source: product_spec). VRT-043198 binds and inhibits caspase-1, blocking its proteolytic activity. This prevents the cleavage of pro-IL-1β and pro-IL-18, thus reducing secretion of these pro-inflammatory cytokines (source: Yuan et al. 2022). VX-765 does not inhibit the production or release of other cytokines such as IL-6, IL-8, IL-α, or TNFα, demonstrating its selectivity (source: product_spec). Its mechanism directly targets the inflammasome–caspase-1–IL-1β/IL-18 axis, making it a precise research tool for dissecting pyroptosis and inflammation.

Evidence & Benchmarks

• VX-765 at 10 μM inhibits caspase-1–dependent pyroptosis in human umbilical vein endothelial cells (HUVECs) exposed to H₂O₂ (source: Yuan et al. 2022).
• Oral administration reduces inflammation and cytokine secretion in mouse models of rheumatoid arthritis and skin inflammation (source: product_spec).
• Prevents dose-dependent CD4 T-cell death (pyroptosis) in HIV-infected lymphoid tissues (source: product_spec).
• VX-765 does not inhibit unrelated cytokines (IL-6, TNFα, IL-8), confirming selectivity (source: product_spec).
• VX-765 and its active metabolite do not directly affect NLRP3 inflammasome assembly, but act downstream at caspase-1 (source: Yuan et al. 2022).

For a broader mechanistic and translational perspective, see VX-765 and the Caspase-1 Frontier (expands on blood-brain barrier models), and Targeting Caspase-1 with VX-765 (provides comparative cytokine selectivity data beyond the current focus).

Applications, Limits & Misconceptions

VX-765 is used for:

• Investigating inhibition of IL-1β and IL-18 release in vitro and in vivo.
• Dissecting mechanisms of pyroptosis inhibition in macrophages and endothelial cells.
• Preclinical research on rheumatoid arthritis and skin inflammation.
• Modeling HIV-associated CD4 T-cell pyroptosis.

Its selectivity allows for clear attribution of results to caspase-1 inhibition. However, VX-765 is not suitable for inhibiting upstream inflammasome activation or non-caspase-1–mediated cell death. It is not effective in pathways independent of the caspase-1–IL-1β/IL-18 axis.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit caspases outside the ICE/caspase-1 subfamily (source: product_spec).
• It is not active against NLRP3 or other upstream inflammasome components (source: Yuan et al. 2022).
• It cannot inhibit apoptosis or necroptosis pathways (source: workflow_recommendation).
• VX-765 is not water-soluble; improper solvent use may compromise assay fidelity (source: product_spec).
• Long-term solution storage is not recommended due to compound instability (source: product_spec).

For a comprehensive review of VX-765’s selectivity and translational research, see VX-765: Selective Caspase-1 Inhibitor for Inflammation and Autoimmune Disease Models, which emphasizes its use in autoimmune models, whereas this article provides updated application and parameter details.

Workflow Integration & Parameters

Protocol Parameters

• Pyroptosis inhibition in HUVECs | 10 μM | in vitro, cell-based | Mirrors conditions validated in endothelial cell pyroptosis assays | DOI: Yuan et al. 2022
• Solubility in DMSO | ≥313 mg/mL | stock preparation | Ensures high-concentration stock for in vitro/in vivo use | product_spec
• Solubility in ethanol | ≥50.5 mg/mL (with ultrasonic assistance) | alternative solvent | For ethanol-based workflows where DMSO is not preferred | product_spec
• Storage temperature | -20°C, desiccated | chemical stability | Preserves activity for short-term use | product_spec
• Use with suc-YVAD-pNA substrate | variable | enzymatic assay | Standard for caspase-1 activity quantification | workflow_recommendation

Why this cross-domain matters, maturity, and limitations

VX-765’s validated inhibition of caspase-1–mediated pyroptosis is supported in both cardiovascular (endothelial dysfunction) and infectious disease (HIV) models. This cross-domain utility is enabled by the shared dependence of both disease processes on IL-1β/IL-18 signaling and caspase-1–mediated cell death (source: Yuan et al. 2022; product_spec). However, it remains ineffective where cell death or inflammation is caspase-1 independent.

Conclusion & Outlook

VX-765, offered by APExBIO as A8238, is a rigorously characterized, selective oral caspase-1 inhibitor suitable for dissecting IL-1β/IL-18–driven inflammation and pyroptosis. Its efficacy is established across cardiovascular and infectious disease models, with clear boundaries in selectivity and solubility (source: Yuan et al. 2022; product_spec). Future research will refine its applications in mechanistic and translational studies, advancing the understanding of inflammasome-driven pathology.